Northwest Biotherapeutics

('NWBT' or the 'Company')

Management and Board Change 

Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO.US), announced that on August 12, 2008, Anthony P. Deasey resigned as Senior Vice President of Finance, Chief Financial Officer and ex officio Director of Northwest Biotherapeutics, Inc. (the 'Company') in order to pursue a personal entrepreneurial opportunity.  

Day to day responsibilities related to the Company's accounting and financial administration will remain with the Company controller. Other financial functions, including pursuit of funding opportunities, will be carried out by the Company's Chief Executive Officer, Dr. Alton Boynton, and the Company's Chairperson, Ms. Linda Powers.  Although Mr. Deasey will discontinue his roles as an officer and ex officio director of the Company effective August 12, Mr. Deasey's employment with the Company will continue until September 30, 2008, to help facilitate the transition.  In addition, from October 1, 2008, through November 15, 2008, Mr. Deasey will provide part-time consulting services to the Company, and will receive consulting fees at a rate equal to 50% of his current monthly salary.

Dr. Alton Boynton, President and Chief Executive Officer commented: 'We would like to thank Tony for his work at Northwest Biotherapeutics over the last year. We wish him well in his future entrepreneurial endeavours and are pleased to have him continue his services as a part-time consultant to the Company while he transitions to his new opportunity.'  Mr. Deasey added, 'I enjoyed working with the Northwest Biotherapeutics team, over the past year, to advance this exciting technology, and wish them continued success.' 

For further information, please contact: